Reckitt Benckiser Ireland Limited
Summary of Product Characteristics last updated on medicines.ie: 22/5/2017
Strepsils Orange with Vitamin C 100mg Lozenges
Strepsils Orange with Vitamin C Lozenges
2, 4-Dichlorobenzyl Alcohol 1.2mg
Vitamin C 100mg
Each lozenge contains 0.6 mg Amylmetacresol, 1.2 mg 2, 4-Dichlorobenzyl Alcohol and 100 mg Vitamin C (as Ascorbic Acid and Sodium Ascorbate).
Excipients: Each lozenge also contains 968.5 mg glucose, 1437.9 mg sucrose, 0.162 mg sunset yellow FCF (E110) and 0.016 mg Ponceau 4R (E124).
For a full list of excipients, see section 6.1.
An orange flavoured and coloured circular lozenge. Embossed on both sides with strepsils brand icon.
4.1 Therapeutic indications
For the symptomatic relief of mouth and throat infection.
4.2 Posology and method of administration
The lowest effective dose should be used for the shortest duration necessary to relieve symptoms. It is recommended that the product should be used for a maximum of 3 days.
Adults: One lozenge every 2-3 hours. Do not take more than 12 lozenges in 24 hours.
Children over 6 years of age:
As above for adults.
Children under 6 years of age:
Not suitable for children under 6 years (see section 4.4)
There is no need for dosage reduction in the elderly.
Method of administration:
For oromucosal administration. To be dissolved slowly in the mouth.
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency should not take this medicine.
4.4 Special warnings and precautions for use
This product is not recommended for young children due to a risk of choking.
Consult your doctor if symptoms persist or if anything unusual happens.
The colours Sunset yellow FCF and Ponceau 4R may cause allergic reactions.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
Contains 0.968491g glucose and 0.14379g sucrose per dose. This should be taken into account in patients with diabetes mellitus.
4.5 Interaction with other medicinal products and other forms of interaction
No clinically significant interactions are known.
4.6 Pregnancy and lactation
There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of amylmetacresol, 2,4-dichlorobenzyl alcohol and ascorbic acid in pregnant women. As a precautionary measure, it is preferable to avoid the use of Strepsils during pregnancy.
Ascorbic acid or metabolites are excreted in human milk, but at therapeutic doses of the product no effects pm breastfed newborns/infants are anticipated. There is insufficient information on the excretion of amylmetacresol or 2,4-dichlorobenzyl alcohol metabolites in human milk. A risk to the newborns/infants cannot be excluded.
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity.
4.7 Effects on ability to drive and use machines
No adverse effects are known.
4.8 Undesirable effects
The list of the following adverse effects relates to those experienced with 2,4- dichlorobenzyl alcohol, amylmetacresol and ascorbic acid at OTC doses, in short term use. In the treatment of chronic conditions, under long-term treatment, additional adverse effects may occur.
Adverse events which have been associated with 2,4-dichlorobenzyl alcohol, amylmetacresol and ascorbic acid are given below, tabulated by system organ class and frequency. Frequencies are defined as: Very common (≥1/10); Common (≥1/100 and <1/10); Uncommon (≥1/1000 and <1/100); Rare (≥1/10,000 and <1/1000); Very rare (< 1/10,000); Not known (cannot be estimated from the available data). Within each frequency grouping, adverse events are presented in order of decreasing seriousness.
System Organ Class
Immune System Disorders
Abdominal painab, nauseaab, oral discomfortab
Skin and Subcutaneous Tissue Disorders
a2,4-dichlorobenzyl alcohol, bamylmetacresol
Reporting of Suspected Adverse Reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Pharmacovigilance Section, Health Products Regulatory Authority, Kevin O'Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: email@example.com
Overdosage should not present a problem other than gastrointestinal discomfort. Treatment should be symptomatic.
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Throat Preparations; Antiseptics;
ATC Code: R02AA03 Dichlorobenzyl alcohol.
Mechanism of action
2,4-Dichlorobenzyl alcohol and amylmetacresol are antiseptics and possess antibacterial, antifungal and antiviral properties. Both AMC and DCBA also reversibly block depolarisation-induced ion channels in a similar way to local anaesthetics. When the two active agents are combined, a synergistic antibacterial action is observed leading to the reduced combined dose used in Strepsils lozenges.
Ascorbic acid and sodium ascorbate provide a source of Vitamin C, which may be beneficial during infection when Vitamin C levels are believed to fall.
Clinical efficacy and safety
Evidence of an analgesic effect for Strepsils in reducing throat soreness, providing pain relief and relief from difficulty in swallowing has been demonstrated to clinical studies with an onset in 5 minutes which lasts for up to 2 hours. Significantly more relief than nonmedical lozenge was also demonstrated for up to 3 days treatment.
Strepsils lozenge have also been shown to significantly decrease postoperative throat soreness and hoarseness 20 minutes and 24 hours after intubation.
A study in children (6-16 years) with acute and recurring chronic sore throat demonstrates a reduction in subjective and objective signs of sore throat over 3 days.
Strepsils Orange with Vitamin C lozenge base has a demulcent action providing throat soothing.
5.2 Pharmacokinetic properties
5.3 Preclinical safety data
6.1 List of excipients
Flavour Blood Orange PHL 105288
Sunset yellow FCF (E110)
Ponceau 4R (E124)
6.3 Shelf life
6.4 Special precautions for storage
Do not store above 25°C
6.5 Nature and contents of container
A clear blister push-through pack consisting of 15 or 20μm hard temper aluminium foil heat sealed to a 250μm or PVC/90gsm PVDC blister. Each blister tray contains 12 lozenges. Two trays are packed in a carton providing a pack size of 24 lozenges. 2 lozenge sample pack.
6.6 Special precautions for disposal and other handling
No special requirements.
Reckitt Benckiser Ireland Ltd.,
Citywest Business Campus,
Date of first authorisation: 24th September 1985
Date of last renewal: 24th September 2010